Cantor Fitzgerald Weighs in on JSPR FY2026 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings of ($3.96) per share for the year. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.24).

A number of other research analysts have also recently commented on JSPR. Oppenheimer decreased their price target on Jasper Therapeutics from $80.00 to $65.00 and set an “outperform” rating on the stock in a research report on Thursday, May 15th. UBS Group decreased their price target on Jasper Therapeutics from $38.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Jasper Therapeutics has an average rating of “Buy” and an average price target of $62.22.

Jasper Therapeutics Trading Down 2.9%

NASDAQ JSPR opened at $5.77 on Tuesday. The company has a market cap of $86.68 million, a price-to-earnings ratio of -1.22 and a beta of 2.72. Jasper Therapeutics has a 1-year low of $3.13 and a 1-year high of $26.05. The company has a 50 day moving average of $4.75 and a 200-day moving average of $8.94.

Institutional Investors Weigh In On Jasper Therapeutics

A number of institutional investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in shares of Jasper Therapeutics by 106.7% in the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after acquiring an additional 3,828 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in Jasper Therapeutics during the fourth quarter worth approximately $223,000. Acadian Asset Management LLC bought a new stake in Jasper Therapeutics in the first quarter worth approximately $46,000. Tema Etfs LLC bought a new stake in Jasper Therapeutics in the fourth quarter worth approximately $266,000. Finally, Rhumbline Advisers lifted its stake in Jasper Therapeutics by 12.6% in the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company’s stock valued at $316,000 after buying an additional 1,652 shares during the period. 79.85% of the stock is owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.